Exogenix
Biotechnology Research • • 1-10 Employees
Company overview
| Headquarters | XX |
| Website | |
| NAICS | 541714 |
| Keywords | Pain Management, Aesthetics, Regenerative Medicine, Stem Cell, Exosomes |
| Employees | 1-10 |
Key Contact at Exogenix
Dan Draper
SE Director
About Exogenix
Next-Generation Exosome Therapeutics | FDA-Aligned | Clinical-Grade | Global Distribution Description: Exogenix is redefining standards in regenerative medicine by providing the only exosome-based injectable biologic manufactured under a 351(a) FDA pathway with an active FDA Master File. Unlike topical serums or research-grade exosomes, our biologics are produced with full clinical oversight, GMP standards, and validated potency — delivering 100B+ CD81+ purified exosomes per vial for consistent, scalable patient outcomes. Who We Serve: We support healthcare providers, aesthetic practices, and pain specialists seeking safe, potent, and compliant regenerative therapies. 💡 What Sets Us Apart: ✅ FDA Master File + IND Pathway (351a Drug) ✅ Injectable + Topical options ✅ GMP manufacturing & ISO-5 cleanroom standards ✅ COA-backed, third-party tested, CD81+ purified ✅ Global distribution & provider support Let’s raise the bar for what regenerative medicine should be. 📍Headquartered in Dallas, TX | Serving global clinical markets
Exogenix revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Exogenix has never raised funding before.
Belgium
United Kingdom
France
SpainFrequently asked questions
4.8
40,000 users
